Close Menu

NEW YORK – OraSure Technologies this week provided updates on its plan to submit a one-step rapid antigen test to detect SARS-CoV-2 to the US Food and Drug Administration for Emergency Use Authorization. The firm will file for prescription-use, self-test and professional use indications by the end of March, with an at-home self-test indication to follow.

With plans to expand its manufacturing capacities, OraSure said it will leverage its existing global relationships to supply the test worldwide for years to come.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.